Related Experiment Video
Updated: Jun 2, 2026
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
Update on malignant pleural mesothelioma
Nicholas Paul Campbell1, Hedy Lee Kindler
1Section of Hematology-Oncology, University of Chicago Medical Center, Chicago, Illinois 60647, USA.
Abstract:
Malignant pleural mesothelioma is an aggressive cancer principally attributable to asbestos. Although the incidence is now declining in the United States, it will continue to increase worldwide until all nations institute regulations limiting asbestos use and exposure. This is a heterogeneous disease, with three pathological subtypes that yield very different outcomes. Stage is less important than histology in determining prognosis. The biomarkers serum mesothelin-related peptide and osteopontin are being evaluated for screening asbestos-exposed individuals and monitoring disease response. The optimal surgical procedure remains controversial because extrapleural pneumonectomy and pleurectomy/decortication can achieve similar results. The reference chemotherapy regimen, pemetrexed-cisplatin, improves survival and quality of life. Key questions about maintenance therapy and the optimal regimens for elderly and frail patients remain to be answered. Although few other cytotoxic drugs have activity, a surprising number of novel agents are being investigated.
Insights
Malignant pleural mesothelioma, an aggressive cancer linked to asbestos, has varied subtypes impacting outcomes. Research is ongoing for biomarkers, surgical approaches, and novel therapies beyond standard chemotherapy.
Area of Science:
- Oncology
- Environmental Medicine
- Pathology
Background:
- Malignant pleural mesothelioma is an aggressive cancer primarily caused by asbestos exposure.
- While US incidence declines, global rates are expected to rise until asbestos use is regulated.
- The disease is heterogeneous, with three subtypes significantly affecting patient prognosis.
Purpose of the Study:
- To review the current understanding and management of malignant pleural mesothelioma.
- To highlight key areas of ongoing research, including biomarkers, surgical techniques, and therapeutic strategies.
Main Methods:
- Literature review of malignant pleural mesothelioma.
- Analysis of prognostic factors, including histology and stage.
- Evaluation of diagnostic biomarkers, surgical options, and chemotherapy regimens.
Main Results:
- Histology is a more critical prognostic factor than stage in malignant pleural mesothelioma.
- Serum mesothelin-related peptide and osteopontin show potential as biomarkers.
- Pemetrexed-cisplatin chemotherapy improves survival and quality of life; optimal regimens for specific patient groups require further study.
Conclusions:
- Malignant pleural mesothelioma management requires consideration of histological subtype and emerging biomarkers.
- Surgical approaches and chemotherapy regimens are evolving, with novel agents under investigation.
- Further research is needed to address unanswered questions regarding maintenance therapy and treatment for vulnerable patient populations.
More Related Videos
Related Concept Videos
01:30Pleural Disorders: Types and Brief Description
01:28Pleural Effusion II: Symptoms and Management
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations: